Hub genes for early diagnosis and therapy of adamantinomatous craniopharyngioma

Yang-Fan Zou, MD\textsuperscript{a,b}, Shu-Yuan Zhang, PhD\textsuperscript{a,b}, Li-Weng Li, MD\textsuperscript{a,b}, Kai Jing, MD\textsuperscript{a,b}, Liang Xia, PhD\textsuperscript{a,b}, Cai-Xing Sun, PhD\textsuperscript{a,b} \textsuperscript{D} Bin Wu, PhD\textsuperscript{a,b,*}

Abstract

**Background:** Adamantinomatous craniopharyngioma (ACP) is a subtype of craniopharyngioma, a neoplastic disease with a benign pathological phenotype but a poor prognosis in the sellar region. The disease has been considered the most common congenital tumor in the skull. Therefore, this article aims to identify hub genes that might serve as genetic markers of diagnosis, treatment, and prognosis of ACP.

**Methods:** The procedure of this research includes the acquisition of public data, identification and functional annotation of differentially expressed genes (DEGs), construction and analysis of protein-protein interaction network, and the mining and analysis of hub genes by Spearman-rho test, multivariable linear regression, and receiver operator characteristic curve analysis. Quantitative real-time polymerase chain reaction was used to detect the level of mRNA of relative genes.

**Results:** Among 2 datasets, a total of 703 DEGs were identified, mainly enriched in chemical synaptic transmission, cell adhesion, odontogenesis of the dentin-containing tooth, cell junction, extracellular region, extracellular space, structural molecule activity, and structural constituent of cytoskeleton. The protein-protein interaction network was composed of 4379 edges and 589 nodes. Its significant module had 10 hub genes, and SYN1, SYP, and GRIA2 were significantly down-regulated with ACP.

**Conclusion:** In a word, we find out the DEGs between ACP patients and standard samples, which are likely to play an essential role in the development of ACP. At the same time, these DEGs are of great value in tumors' diagnosis and targeted therapy and could even be mined as biological molecular targets for diagnosing and treating ACP patients.

**Abbreviations:** ACP = adamantinomatous craniopharyngioma, DEGs = differentially expressed genes, GEO = Gene Expression Omnibus, GO = gene ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes, MCODE = molecular complex detection, MNS = motor neurons, ROC = receiver operator characteristic, RT-qPCR = quantitative real-time polymerase chain reaction.

**Keywords:** adamantinomatous craniopharyngioma, biological information technology, biomarker, differentially expressed genes

1. Introduction

Craniopharyngioma is a neoplastic disease with a benign pathological phenotype but a poor prognosis in the sellar region.\textsuperscript{[1]} The disease has been considered the most common congenital tumor in the skull. The prevalence of the disease is higher in Africa and the far east than in other regions except for Japan, and the tumor presents a bimodal distribution in age, namely, 2 peaks in children and adults aged 40 to 50 years.\textsuperscript{[1]} According to the central nervous system classification of craniopharyngioma published by WHO in 2016, craniopharyngioma is classified into adamantinomatous craniopharyngioma (ACP) and papilloma craniopharyngioma.\textsuperscript{[2]} The former is mainly found in children, while the latter is almost only seen in adults. Because craniopharyngioma locates deep and adjacent to the optic nerve, hypothalamus, basilar artery ring, and other essential structures, surgical treatment is complex, the mortality rate is high, and it is easy to relapse.

In recent years, bioinformatics technology has been widely used to explore the potential genetic targets of diseases and...
help us find the differentially expressed genes and possible pathways related to the occurrence and development of diseases.\(^{13}\) Differentially expressed genes have been found and verified in many diseases and are potential targets for disease prediction and treatment. Bredemeier used the bioinformatics method to identify the critical genes in the occurrence and development of breast cancer, and the results showed that KRT19, EPCAM, CDH1, and SCGB2A2 had significant expression differences.\(^{14}\) Therefore, it is suggested that this gene should be regarded as a therapeutic target. Meanwhile, Feng et al.\(^{15}\) identified 2 IncRNAs, LOC146880 and ENST00000439577, which may promote the development and progression of lung cancer by analyzing gene expression and methylation microarray data. Therefore, bioinformatics technology has unique advantages in mining the differentially expressed genes between patients with the disease and regular patients and searching for the targeted genes related to the occurrence and development of disease.

Based on bioinformatics technology, this study combined spearman correlation analysis and multiple linear regression analysis to screen out the central genes significantly related to ACP. The results of this study may provide important targets for the clinical diagnosis and treatment of ACP and contribute to the clinical treatment and decision-making of ACP. It provides better help for the prognosis and survival of patients with ACP and more possibilities for future treatment of ACP.

2. Methods

2.1. Access to public data

Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo) is an open functional genomics database of high-throughput resources, including microarrays, gene expression data, and chips. Two expression profiling datasets (GSE94349 and GSE68015) were obtained from GEO. The probes would be transformed into the homologous gene symbol using the platform's annotation information. The GSE94349 dataset contained 24 ACP and 27 standard samples, and GSE68015 contained 15 ACP and 16 normal samples.

2.2. DEGs identified by limma package

The limma package screened the differentially expressed genes (DEGs) between ACP and normal samples. After setting up the differential experimental groups for 1 GEO series, the limma package could execute a command to compare the differential classifications to identify the DEGs. According to the method of Benjamin and Hochberg (false discovery rate), the tool could apply adjustment to the P values to obtain the adjusted P values (adj. P) and maintain 1 balance between the possibility of false positives and detection of statistically significant genes. If 1 probe set does not have the homologous gene, or if 1 gene has numerous probe sets, the data will be removed. The rule of statistical significance is that adj. P value ≤ .01 and log (Fold change, FC) ≥ 4 or ≤ −4. The Venn diagram was delineated by FunRich software.

2.3. Functional annotation of DEGs by GO and KEGG analyses

DAVID (https://david.nicifcrf.gov/home.jsp) (version 6.8), 1 online analysis tool suite with the function of Integrated Discovery and Annotation, mainly provides typical batch annotation and gene-gene ontology (GO) term enrichment analysis to highlight the most relevant GO terms associated with a given gene list. Kyoto Encyclopedia of Genes and Genomes (KEGG) (https://www.kegg.jp/), 1 of the world’s most commonly used biological information databases, aims to understand advanced functions and biological systems. From the molecular level, KEGG integrates many practical program database resources from high-throughput experimental technologies. GO is an ontology widely used in bioinformatics, which covers 3 aspects of biology, including cellular component, molecular function, and biological process. The DAVID online tool was implemented to perform GO and KEGG analyses of DEGs. The rule of statistical significance is that P < .05.

2.4. Construction and analysis of PPI network

After importing the common DEGs to the Search Tool for the Retrieval of Interacting Genes (http://string-db.org) (version 10.5), the online tool could predict and trace the protein-protein interaction (PPI) network. The analysis of interactions between various proteins might put forward some novel ideas into the pathophysiological mechanisms of the development of ACP. In this research, the Search Tool for the Retrieval of Interacting Genes database was used to construct the PPI network of DEGs, and the minimum required interaction score is medium confidence > 0.4.

2.5. The analysis and mining of hub genes

Based on the topology principles, the Molecular Complex Detection (MCODE) (version 1.5.1), a plug-in of Cytoscape, could discover the tightly coupled region. MCODE identified the most important module of the PPI network map. The criteria of MCODE analysis require that degree cut-off = 2, MCODE scores > 5, Max depth = 100, k-score = 2, and node score cut-off = 0.2. The hub genes were excavated when the degrees were set (degrees ≥ 10). Then, DAVID online tool was used to analyze the GO and KEGG pathway analyses for the hub genes. The clustering analysis of hub genes was performed using OmicShare (http://www.omicshare.com/tools), an available data analysis platform.

The Spearman-rho test was used for correlation analysis between ACP and relevant gene expression. Any test results reaching a liberal statistical threshold of P < .2 for each comparison were then entered into a multivariable linear regression model to identify independent predictive genes of ACP. Finally, we performed receiver operator characteristic (ROC) curve analysis to determine the ability of the hub genes to predict ACP. All statistical analyses were conducted using SPSS software (version 21.0; IBM, Armonk, NY). A P value of <0.05 was considered statistically significant.

2.6. Quantitative real-time polymerase chain reaction (RT-qPCR) assay

A total of 14 participants were recruited, including 7 control individuals and 7 ACP patients. After surgery, 7 ACP tumor samples from ACP patients and 7 control brain samples from control individuals were obtained. The research conformed to the Declaration of Helsinki and was authorized by the Human Ethics and Research Ethics Committees of the Zhejiang Cancer Hospital. Informed consent was obtained from all participants.

Total RNA was extracted from 7 ACP tumors and 7 control brain samples by the RNAiso Plus (Trizol) kit (Thermofisher, Massachusetts, United States, MA) and reverse transcribed to cDNA. RT-qPCR was performed using a Light Cycler® 4800 System (Roche Diagnostic Products Co., Basel, Switzerland) with specific GRIA2, SYN1, and SYP primers. Table 1 presents the primer sequences used in the experiments. The RQ values (2−ΔΔC\text{t}, where Ct is the threshold cycle) of each sample were calculated and are presented as fold changes in gene expression relative to the control group. GAPDH was used as an endogenous control.
3. Results

3.1. DEGs identified between standard and ACP samples

After analysis of the datasets (GSE94349 and GSE68015) with the limma package, the difference between ACP and standard samples could be presented in the volcano plots (Fig. 1A and B). Then these results were standardized, and DEGs (944 in GSE94349 and 764 in GSE68015) were distinguished. The Venn diagram could show that 703 genes were simultaneously contained in the 2 datasets (Fig. 1C).

3.2. Functional annotation of DEGs by GO and KEGG analyses

The results of GO analysis presented that variations in biological processes, cellular component, and molecular function of DEGs were mainly enriched in chemical synaptic transmission, cell adhesion, epidermis development, extracellular matrix organization, odontogenesis of the dentin-containing tooth, cell junction, extracellular region, plasma membrane, extracellular space, axon, structural molecule activity, calcium ion binding, Gamma-aminobutyric acid-A (GABA-A) receptor activity, and structural constituent of the cytoskeleton (Table 2). Analysis of the KEGG pathway displayed that all DEGs were primarily enriched in retrograde endocannabinoid signaling, nicotine addiction, extracellular matrix-receptor interaction, morphine addiction, and GABAergic synapse (Table 2).

3.3. PPI and module networks construction and hub gene selection

The PPI network of DEGs was constructed (Fig. 2), and the most powerful module was obtained using Cytoscape (Fig. 3). A total of 10 genes (SNAP25, GRIA2, KCNJ9, SYN1, SLC32A1, SNCB, GRM5, GABRG2, SYP, and CDH1) were identified as hub genes with degrees ≥ 10 (Fig. 4A).

3.4. Hub gene analysis

The functional analyses of hub genes were analyzed using DAVID. Results showed that hub genes were mainly enriched in chemical synaptic transmission, neurotransmitter secretion, regulation of long-term neuronal synaptic plasticity, locomotory behavior, cell junction, presynaptic active zone, neuron projection, synaptic vesicle, calcium-dependent protein binding, retrograde endocannabinoid signaling, nicotine addiction, morphine addiction, and neuroactive ligand-receptor interaction (Table 3). The names, abbreviations, and functions for these hub genes are shown in Table 4. Hierarchical clustering showed that the hub genes could differentiate the ACP samples from normal ones (Fig. 4B and C). These hub genes showed the highest node score in the PPI network, suggesting that they might play essential roles in the occurrence or progression of ACP.

3.5. Correlation between ACP and hub genes expression

To ensure that the hub genes impacted ACP, we performed a further analysis of ACP and hub gene expression. Spearman correlation coefficient was used in the correlation analysis, and SNAP25 ($\rho = -0.702$, $P < .001$), GRIA2 ($\rho = -0.673$, $P < .001$), KCNJ9 ($\rho = -0.706$, $P < .001$), SYN1 ($\rho = -0.747$, $P < .001$), SLC32A1 ($\rho = -0.813$, $P < .001$), SNCB ($\rho = -0.848$, $P < .001$), GRM5 ($\rho = -0.680$, $P < .001$), GABRG2 ($\rho = -0.830$, $P < .001$), SYP ($\rho = -0.852$, $P < .001$), and CDH1 ($\rho = -0.865$, $P < .001$) were significantly correlated with ACP (Table 5).

3.6. The hub genes could predict ACP sensitively and significantly by the ROC curve

We constructed receiver operator characteristic curves to identify accurate thresholds for hub genes predicting ACP. SYP was mostly associated with higher risk of ACP (area under the curve for ACP, 0.992; 95% confidence interval, 0.980–1.000; $P < .001$). The optimal diagnostic threshold of SYP for ACP was 5.672. (Table 6; Fig. 5A–K).

Table 1

| Primer | Sequence (5’–3’) |
|--------|-----------------|
| GRIA2-hF | CACCCCAATCATGCAAATTG6 |
| GRIA2-hR | CACCCCAATCATGCAAATTG6 |
| SYN1-hF | AGTTCTGGCGATGGTCCCA |
| SYN1-hR | AGTTCTGGCGATGGTCCCA |
| SYP-hF | CTCGCGGCTTGGAAAGCTGGCT |
| SYP-hR | CTCGCGGCTTGGAAAGCTGGCT |

Figure 1. The identification of DEGs by limma package and Venn diagram. (A) The volcano plot presents the difference between ACP and normal samples after analysis of the datasets GSE94349 with limma package. (B) The volcano plot presents the difference between non-MM lung cancer and MM lung cancer tissues after analysis of the datasets GSE68015 with limma package. (C) The Venn diagram could show that 703 genes were contained in the GSE94349 and GSE68015 datasets simultaneously. ACP = adamantinomatous craniopharyngioma, DEGs = differentially expressed genes, MM = multiple myeloma.
Table 2
GO and KEGG pathway enrichment analysis of DEGs in ACP samples.

| Term          | Description                      | Count in gene set | FDR  |
|---------------|----------------------------------|-------------------|------|
| GO:0007268    | Chemical synaptic transmission    | 42                | 8.95E-03 |
| GO:0007155    | Cell adhesion                     | 50                | 1.40E-09 |
| GO:0008544    | Epidermis development             | 20                | 7.22E-08 |
| GO:0030198    | Extracellular matrix organization | 28                | 8.67E-07 |
| GO:0042475    | Osteogenesis of dentin-containing tooth | 15           | 4.37E-06 |
| GO:0030054    | Cell junction                     | 65                | 3.18E-19 |
| GO:0005576    | Extracellular region              | 121               | 4.93E-14 |
| GO:0005886    | Plasma membrane                   | 222               | 3.54E-11 |
| GO:0005615    | Extracellular space               | 100               | 1.72E-10 |
| GO:0030424    | Axon                              | 32                | 2.97E-08 |
| GO:0005198    | Structural molecule activity       | 35                | 2.77E-09 |
| GO:0005509    | Calcium ion binding               | 62                | 1.91E-08 |
| GO:0004890    | GABA-A receptor activity          | 8                 | 0.002 |
| GO:0005200    | Structural constituent of cytoskeleton | 16          | 0.005 |
| hsa04723      | Retrograde endocannabinoid signaling | 23           | 6.94E-10 |
| hsa05033      | Nicotine addiction                | 15                | 1.23E-08 |
| hsa04512      | ECM-receptor interaction           | 17                | 1.58E-05 |
| hsa05032      | Morphine addiction                | 16                | 2.10E-04 |
| hsa04727      | GABAergic synapse                 | 15                | 5.55E-04 |

ACP = adamantinomatous craniopharyngioma, DEGs = differentially expressed genes, ECM = extracellular matrix, FDR = false discovery rate, GO = gene ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes.

3.7. Results of RT-qPCR analysis

According to the analysis above, GRIA2, SYN1, and SYP were markedly down-regulated in ACP tumor samples. As presented in Figure 6, the relative expression levels of GRIA2, SYN1, and SYP were significantly lower in ACP samples compared with the control groups. The result demonstrated that GRIA2, SYN1, and SYP might be considered biomarkers for ACP.

4. Discussion

ACP is a congenital histologically benign but aggressive and invasive epithelial tumor of the saddle area. Current ACP treatment is still dominated by surgical resection. However, due to the complicated and essential anatomical relationships around tumor and tumor itself factors, the total surgical resection rate is low, operative mortality and incidence of severe complications and the postoperative recurrence rate are high, and the complete resection rate reported in the literature was only 18% to 84%, the postoperative mortality was as high as 1.7% to 5.4%, and the 10-year recurrence rate of patients with total tumor resection was 0% to 62%. Long-term hypophysitis and hypothalamic dysfunction are also complex problems in neurosurgery for many years. Molecular biological targeted therapy for craniopharyngioma with BRAF mutation has become a research hotspot.[7] In 2016, gene blockers were used for the clinical treatment of patients with craniopharyngioma, and preliminary observation found that the tumor volume after treatment was significantly reduced.[8] Currently, phase II clinical trials are underway, and it still takes some time to use targeted molecular therapy widely. And there is a lack of molecular biological markers to predict the efficacy and prognosis of ACP patients.

Biological information technology can screen out the differentially expressed genes between tumor patients and normal individuals through the mining and utilization of gene databases and then use them as potential genetic, molecular markers for tumor diagnosis and prognosis. At present, this technique has been used to screen differentially expressed genes in a variety of tumors and has broad application value.

We use bioinformatics technology to screen 2 gene expression data sets, the ACP and normal individuals screen out 703 differentially expressed genes, further analysis found the ten most significant hub genes, and through the GO, KEGG analysis to find out the function and pathway of this differential gene enrichment, to further explore the possible mechanism of these differentially expressed genes on disease. In spearman correlation analysis and multiple linear regression analysis, CDH1 was closely related to ACP, indicating that it might have significant statistical significance in the occurrence and development of ACP. However, in ROC analysis, the AUC expression was zero, indicating that the results had low authenticity and no application value. Therefore, it has no diagnostic value for the direction of this study. Finally, Spearman correlation, multiple linear regression, and ROC curve analysis were used to screen and identify the 3 hub genes (SYN1, SYP, and GRIA2) most valuable for ACP diagnosis. SYN1, SYP, and GRIA2 had significant statistical significance in the occurrence and development of ACP.

The SYN1 gene encodes a neuronal phosphoprotein that covers synaptic vesicles and binds to the cytoskeleton, which is thought to play an essential role in regulating the release of neurotransmitters.[10] Some scholars have found that SYN1 gene mutation causes changes in neuron development and nerve ending function and causes some diseases related to synaptic dysfunction, such as autism and epilepsy.[11] At the same time, it has been found that low expression of SYN1 may maintain malignant tumor proliferation and promote the occurrence and development of glioma.[12] Similar to these findings, we also found that this gene is highly expressed in normal individuals and low expression may correlate with disease.
Figure 3. The significant module network was identified from the PPI network. PPI = protein-protein interaction.

Figure 4. The mining and analysis of hub genes. (A) There were 10 genes (SNAP25, GRIA2, KCNJ9, SYN1, SLC32A1, SNCB, GRM5, GABRG2, SYP, and CDH1) identified as hub genes with degrees ≥10. (B) Hierarchical clustering showed that the hub genes could differentiate the ACP samples from the normal ones in the datasets GSE94349. (C) Hierarchical clustering showed that the hub genes could differentiate the ACP samples from the normal ones in the datasets GSE68015. Upregulation of genes is marked in red; downregulation is observed in green. ACP = adamantinomatous craniopharyngioma.
Table 3

GO and KEGG pathway enrichment analysis of hub genes.

| Term          | Description                                             | Count in gene set | P value | FDR   |
|---------------|---------------------------------------------------------|-------------------|---------|-------|
| GO:0007268    | Chemical synaptic transmission                         | 5                 | 4.85E-06 | 0.005 |
| GO:0007269    | Neurotransmitter secretion                             | 3                 | 3.21E-04 | 0.333 |
| GO:0048169    | Regulation of long-term neuronal synaptic plasticity   | 2                 | .010    | 9.535 |
| GO:0007626    | Locomotory behavior                                    | 2                 | .044    | 37.410|
| GO:0030054    | Cell junction                                           | 6                 | 1.15E-06 | 0.001 |
| GO:0048786    | Presynaptic active zone                                | 3                 | 8.74E-05 | 0.088 |
| GO:0043005    | Neuron projection                                      | 4                 | 1.72E-04 | 0.172 |
| GO:0008021    | Synaptic vesicle                                       | 3                 | 8.87E-04 | 0.885 |
| GO:0048306    | Calcium-dependent protein binding                       | 2                 | .031    | 24.422|
| hsa04723      | Retrograde endocannabinoid signaling                   | 5                 | 6.42E-07 | 5.61E-04|
| hsa05033      | Nicotine addiction                                     | 3                 | 4.87E-04 | 0.425 |
| hsa05032      | Morphine addiction                                     | 3                 | .003    | 2.168 |
| hsa04080      | Neuroactive ligand-receptor interaction                | 3                 | .022    | 17.477|

FDR = false discovery rate, GO = gene ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes.

Table 4

Summaries for the function of 10 hub genes.

| No. | Gene symbol | Full name                                      | Function                                                                 |
|-----|-------------|-----------------------------------------------|--------------------------------------------------------------------------|
| 1   | SNAP25      | Synaptosome Associated Protein 25             | Regulating neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems |
| 2   | GRIA2       | Glutamate Ionotropic Receptor AMPA Type Subunit 2 | Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission |
| 3   | KCNJ9       | Potassium Voltage-Gated Channel Subfamily J Member 9 | The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, is controlled by G-proteins |
| 4   | SYN1        | Synapsin 1                                     | Neuronal phosphoprotein that coats synaptic vesicles, binds to the cytoskeleton, and is believed to function in the regulation of neurotransmitter release |
| 5   | SLC32A1     | Solute Carrier Family 32 Member 1             | Involved in the uptake of gamma-aminobutyric acid (GABA) and glycine into the synaptic vesicles |
| 6   | SNCB        | Synuclein Beta                                 | This gene encodes a member of a small family of proteins that inhibit phospholipase D2 and may function in neuronal plasticity |
| 7   | GRM5        | Glutamate Metabotropic Receptor 5             | Plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity |
| 8   | GABRG2      | GABA Type A Receptor Gamma 2 Subunit 2        | Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine |
| 9   | SYP         | Synaptophysin                                  | Possibly involved in structural functions as organizing other membrane components or in targeting the vesicles to the plasma membrane. Involved in the regulation of short-term and long-term synaptic plasticity |
| 10  | CDH1        | Cadherin 1                                     | Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types |

Table 5

The correlation and linear regression analysis between ACP and relevant gene expression.

| Gene symbol | Spearman correlation coefficient ρ | P value | β | Multiple linear regression P value |
|-------------|-----------------------------------|---------|---|----------------------------------|
| SNAP25      | −0.702                            | <.001*  | −0.040 | .138 |
| GRIA2       | −0.673                            | <.001*  | 0.044  | .041* |
| KCNJ9       | −0.706                            | <.001*  | 0.021  | .386 |
| SYN1        | −0.747                            | <.001*  | 0.083  | .017* |
| SLC32A1     | −0.813                            | <.001*  | −0.009 | .692 |
| SNCB        | −0.848                            | <.001*  | 0.054  | .108 |
| GRM5        | −0.680                            | <.001*  | −0.005 | .823 |
| GABRG2      | −0.830                            | <.001*  | 0.036  | .326 |
| SYP         | −0.852                            | <.001*  | −0.137 | <.001* |
| CDH1        | 0.865                             | <.001*  | 0.154  | <.001* |

ACP = adamantinomatous craniopharyngioma, β = parameter estimate, ρ = Spearman correlation coefficient.

*Significant variables; P < .05.
†Spearman rank correlation coefficient between ACP and relevant characteristics.
‡Multiple linear regression analysis.
in ACP patients. Since tumor progression and poor prognosis are often associated with the synaptic function of tumor cells,[13] we speculated that mutations in this gene were involved in the development and progression of ACP by causing changes in synaptic plasticity. These data suggest that the SYN1 gene and its target proteins can serve as potential, genetic, and molecular targets for ACP prevention and treatment.

Binding to small synaptic vesicles found in the nerve terminals, SYN1 possibly has an exocytic regulatory role in linking the vesicles to the cytoskeleton and each other.[14-16] Furthermore, SYN1 is likely involved in neuronal development and the formation of synaptic contacts between neurons.[17-19] The mutations create changes in the SYN1 protein, potentially causing defects in synaptic vesicle traffic and nerve terminal function. Following its native position, SYN1 is found to be brain- and neuron-specifically expressed mediated by the promoter region of the SYN1 gene.[20] The SYN1 protein serves as a substrate for several different protein kinases, and phosphorylation is likely functioning in regulating this protein in the nerve terminal.

SYP coding protein is involved in forming intracellular vesicles and other membrane components, and it can regulate the short-term and long-term plasticity of synapses.[21] Since the interruption of synaptic plasticity is the basis of learning and memory, some scholars believe that SYP is involved in the occurrence and development of Alzheimer disease.[22] At the same time, studies have shown that the synapse complex protein syp-1 formed by its encoding protein affects the formation of some critical protein domains through phosphorylation, which further affects cell mitosis and plays an essential role in maintaining the normal cell cycle.[23] SYP is a specific marker protein of synaptic vesicles, and its density and distribution indirectly reflect the number and distribution of synaptic vesicles.[24] Other scholars have found that syp-3 can inhibit PI3K/AKT- and MAPK/erk-dependent hif-1 pathways and inhibit the migration and invasion of tumor cells and tumor angiogenesis.[25] Through bioinformatics technology, we found that the low expression of GRIA2 in ACP patients may be the abnormal expression of the signal pathway related to the glutamate energy system, leading to the occurrence and development of ACP and suggesting that GRIA2 can be used as a potential target for ACP diagnosis and treatment.

Table 6

| Gene symbol | AUC  | P value | 95% CI | ODT |
|-------------|------|---------|-------|-----|
| SNAP25      | 0.906| <.001*  | 0.831–0.980 | 11.476 |
| GRIA2       | 0.889| <.001*  | 0.810–0.968 | 10.564 |
| KCNN9       | 0.908| <.001*  | 0.841–0.975 | 8.828  |
| SV2T        | 0.932| <.001*  | 0.868–0.996 | 6.027  |
| SLC32A1     | 0.970| <.001*  | 0.940–1.000 | 2.090  |
| SCNB        | 0.990| <.001*  | 0.976–1.000 | 2.920  |
| GRM5        | 0.893| <.001*  | 0.828–0.959 | 7.121  |
| GABRB2      | 0.980| <.001*  | 0.958–1.000 | 9.471  |
| SYP         | 0.992Max| <.001* | 0.980–1.000 | 5.672  |
| CDH1        | 0.000| <.001*  | 0.000–0.000 | 1.400  |

ACP = adamanotinomatous crianiopharyngioma, AUC = area under curve, CI = confidence interval, max = the maximum of AUC, ODT = optimal diagnostic threshold.

*Significant variables.

GRIA2 encoded glutamate receptors play an important role in central nervous system gated ion channels and excitatory synaptic transmission. Earlier studies found that the knockout of the GRIA2 gene in mice can affect learning and food-reward stimulation.[29] Recently, it has been found that the GRIA2 gene is differentially expressed in patients with a good prognosis of ovarian serous papillary adenocarcinoma after chemotherapy, suggesting the role of GRIA2 in determining the prognosis of patients with chemotherapy.[30] It has also been found that compared with normal individuals, the abnormal expression of GRIA2 in isolated fibrous tumors was statistically different.[31] However, some scholars believe this gene increases the invasion and migration of pancreatic cancer cells by activating the AMPA receptor and the classical MAPK pathway. GRIA2 is involved in the degeneration of the brain and spinal motor neurons caused by amyotrophic lateral sclerosis. Its mechanism may be the abnormal signal pathway caused by its transcriptional mRNA and the interference of Ca2+ homeostasis. Other studies have suggested that the glutamate system may be involved in the development of migraine.[32] However, through bioinformatics technology, we found that the low expression of GRIA2 in ACP patients may be the abnormal expression of the signal pathway related to the glutamate energy system, leading to the occurrence and development of ACP and suggesting that GRIA2 can be used as a potential target for ACP diagnosis and treatment.

Hub proteins are an essential part of interactors in the organism. They bind to different interacting partners, and most of which are transcription factors or co-regulators involved in signaling pathways. It shows remarkable pleiotropy and connects many cellular systems. Static centers interact with their partners simultaneously, while dynamic centers bind to different partners at different places and times.[33] However, our study still has many shortcomings, such as the lack of animal experiments to verify whether abnormal expression of these genes can trigger ACP. The experiment’s sample

level may be closely related to the malignant degree of ACP and the survival prognosis of patients.[27-28]
size is small, which may affect the results to some extent. In future studies, larger sample sizes will be used for analysis, and more reliable statistical values will be obtained through higher sample sizes.

In a word, by screening the gene database, we find out that ACP patients differentially expressed genes are likely to play an essential role in the development of ACP. At the same time, these differentially expressed genes are of great value in the diagnosis of ACP = adamantinomatous craniopharyngioma.

Figure 5. The receiver operator characteristic curves indicate that the hub genes could predict ACP sensitively and especially. (A) SNAP25, (B) GRIA2, (C) KCNJ9, (D) SYN1, (E) SLC32A1, (F) SNCB, (G) GRM5, (H) GABRG2, (I) SYP, (J) CDH1, (K) The merger of all hub genes.
and targeted therapy of tumors and can even be mined as a biological molecular target for the prognosis and prognosis of ACP patients, which has broad application prospects.

Author contributions

Y-FZ and S-YZ experimented and were significant contributors to writing and submitting the manuscript. BW and C-XS made substantial contributions to research conception. They also designed the draft of the research process. Y-FZ and LX were involved in critically revising the manuscript for important intellectual content. BW, L-WL and KJ analyzed the genomic data regarding Glioblastoma. All authors read and approved the final manuscript.

Conceptualization: Liang Xia, Cai-Xing Sun, Bin Wu.

Formal analysis: Li-Weng Li, Kai Jing.

Investigation: Yang-Fan Zou, Shu-Yuan Zhang, Li-Weng Li.

Project administration: Li-Weng Li, Cai-Xing Sun.

Resources: Bin Wu.

Software: Shu-Yuan Zhang.

Supervision: Kai Jing.

Validation: Shu-Yuan Zhang, Kai Jing.

Visualization: Kai Jing.

Writing – original draft: Yang-Fan Zou, Shu-Yuan Zhang, Liang Xia, Bin Wu.

Writing – review & editing: Yang-Fan Zou, Liang Xia, Bin Wu.

References

[1] Muller HL. Craniopharyngioma. Endocr Rev. 2014;35:513–43.
[2] Sahm F, Reuss DE, Giannini CW. 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours. Neuropathol Appl Neurobiol. 2018;44:163–71.
[3] Wilson HE, Rhodes KK, Rodriguez D, et al. Human breast cancer xenograft model implicates peroxisome proliferator-activated receptor signaling as driver of cancer-induced muscle fatigue. Clin Cancer Res. 2019;25:2336–47.
[4] Bredemeier M, Edimiris P, Mach P, et al. gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer. Clin Chem. 2017;63:1585–93.
[5] Feng N, Ching T, Wang Y, et al. Analysis of microarray data on gene expression and methylation to identify long non-coding RNAs in non-small cell lung cancer. Sci Rep. 2016;6:37233.
[6] Muller HL, Merchant TE, Puget S, et al. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol. 2017;13:299–312.
[7] Brastanouos PK, Shankar GM, Gill CM, et al. Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. 2016;108:dv5310.
[8] Sun HI, Akgun E, Bicer A, et al. Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence. Neurosurgery. 2016;60:744–50, discussion 750.
[9] Miao R, Luo H, Zhou H, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014;61:840–9.
[10] Guarnieri FC, Pozzi D, Raimondi A, et al. A novel SYN1 missense mutation in non-syndromic X-linked intellectual disability affects synaptic vesicle life cycle, clustering and mobility. Hum Mol Genet. 2017;26:699–714.
[11] Giannandrea M, Guarnieri FC, Gehring NH, et al. Nonsense-mediated mRNA decay and loss-of-function of the protein underlie the X-linked epilepsy associated with the W356X mutation in synapsin I. PLoS One. 2013;8:e67724.
[12] Yucebas M, Yilmaz Suslu S, Onur Caglar H, et al. Expression profiling of RE1-silencing transcription factor (REST), REST corepressor 1 (RCOR1), and Synapsin 1 (SYN1) genes in human gliomas. J BUON. 2016;21:964–72.
[13] Steinestel K, Glasle F, Bruderlein S, et al. [Abelson interactor 1 (Abi1) in colorectal cancer. from synaptic plasticity to tumor cell migration]. Pathologie. 2013;34(Suppl 2):189–94.
[14] Bihler M, Greengard P. Synapsin I bundles F-actin in a phosphorylation-dependent manner. Nature. 1987;326:704–7.
[15] Schiebler W, Jahn R, Doucet JP, et al. Characterization of synapsin I binding to small synaptic vesicles. J Biol Chem. 1986;261:8383–90.
[16] Baines AJ, Bennett V. Synapsin I is a microtubule-bundling protein. Nature. 1986;319:145–7.
[17] Lu B, Greengard P, Poo MM. Exogenous synapsin I promotes functional maturation of developing neuromuscular synapses. Neuron. 1992;8:521–9.
[18] Melloni RH Jr, Apostolides PJ, Hamos JE, et al. Dynamics of synapsin I gene expression during the establishment and restoration of functional synapses in the rat hippocampus. Neuroscience. 1994;58:633–703.
[19] Valtorta F, Iezzi N, Benfenati F, et al. Accelerated structural maturation induced by synapsin I at developing neuromuscular synapses of Xenopus laevis. Eur J Neurosci. 1995;7:261–70.
[20] Schoch S, Cibelli G, Thiel G. Neuro-species-specific gene expression of synapsin I. Major role of a negative regulatory mechanism. J Biol Chem. 1996;271:3173–217.
[21] Micurevic-Vasiljkovic N, Pesic V, Tanic N, et al. Changes in markers of neuronal and glial plasticity after cortical injury induced by food restriction. Exp Neurol. 2009;220:133–9.
[22] Chi LM, Wang X, Nan GX. In silico analyses for molecular genetic mechanism and candidate genes in patients with Alzheimer’s disease. Acta Neurol Belg. 2016;116:543–7.
[23] Sato-Carlton A, Nakamura-Tabuchi C, Chartrand SK, et al. Phosphorylation of the synaptosomal complex protein SYP-1 promotes meiotic chromosome segregation. J Cell Biol. 2018;217:555–70.
[24] Hani J, Vafaei-Nezhad S, Sadeghi A, et al. Synaptogenesis in the cerebellum of offspring born to diabetic mothers. J Pediatr Neurosci. 2017;12:215–21.
[25] Wang LH, Jiang XR, Yang JY, et al. SYP-5, a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. Eur J Pharmacol. 2016;791:560–8.
[26] Kolos YA, Grigoriyev IP, Korzhevskyi DE. A synaptic marker synapto-physin. Morfologiia. 2015;147:78–82.

[27] Pietsch T, Schmidt R, Remke M, et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014;128:137–49.

[28] Rodriguez FJ, Perry A, Rosenblum MK, et al. Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. Acta Neuropathol. 2012;124:627–41.

[29] Mead AN, Brown G, Le Merrer J, et al. Effects of deletion of gria1 or gria2 genes encoding glutamatergic AMPA-receptor subunits on place preference conditioning in mice. Psychopharmacology (Berl). 2005;179:164–71.

[30] Choi CH, Choi JJ, Park YA, et al. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival. Br J Cancer. 2012;107:91–9.

[31] Vivero M, Doyle LA, Fletcher CD, et al. GRIA2 is a novel diagnostic marker for solitary fibrous tumour identified through gene expression profiling. Histopathology. 2014;65:71–80.

[32] Gasparini CF, Smith RA, Griffiths LR. Genetic insights into migraine and glutamate: a protagonist driving the headache. J Neurol Sci. 2016;367:258–68.

[33] Jespersen N, Barbar E. Emerging features of linear motif-binding hub proteins. Trends Biochem Sci. 2020;45:375–84.

[34] Ota M, Gonja H, Koike R, et al. Multiple-Localization and hub proteins. PLoS One. 2016;11:e0156455.

[35] Sugitani N, Chazin WJ. Characteristics and concepts of dynamic hub proteins in DNA processing machinery from studies of RPA. Prog Biophys Mol Biol. 2015;117:206–11.